GLP-1 exit plan: what a proper review should include

Why a proper review is not a prescription cancellation

Most patients who stop GLP-1 medication do so by stopping. No clinical review, no monitoring plan, no medication adjustment, no written document. This is the equivalent of stopping a blood pressure drug with no follow-up — plausible if nothing goes wrong, problematic when predictable consequences occur without a plan to manage them.

A proper GLP-1 exit review is not a bureaucratic hurdle. It is the clinical step that most changes outcomes in the transition off these medications. The difference between a planned and unplanned stop is measurable — in regain rates, in blood pressure events, in diabetes deterioration, and in the speed at which cardiometabolic gains are surrendered.

Component 1: the clinical history of treatment

A useful review begins with a clear account of what happened during treatment: starting weight, current weight, waist circumference, dose history, reason for starting, indication, comorbidities at baseline, and any medication changes during treatment. This is not administrative — it determines what risks are present at the point of stopping and what monitoring priorities are highest.

A patient who lost 20 kg and had antihypertensives reduced during treatment faces a different stopping picture from a patient who lost 7 kg and is on no other medications. Both may be stopping at "target weight," but their review should look entirely different.

Component 2: blood pressure and medication review

Blood pressure, checked sitting and standing, reviewed against current antihypertensive medication and the weight change context. This is the most immediately actionable component of a stopping review — orthostatic hypotension can develop within days of medication changes, not weeks. [1] If blood pressure has fallen significantly during treatment, the antihypertensive dose may need reducing before stopping the GLP-1 agent, not after.

Component 3: metabolic blood tests

HbA1c if diabetic or pre-diabetic. Fasting lipids if cardiovascular risk was part of the indication. Kidney function if there is any history of renal impairment. Liver enzymes if fatty liver disease was documented at baseline. These provide a metabolic snapshot before stopping — a baseline against which to measure change in the weeks and months after. [2] They also identify findings that might change the stopping decision or timeline.

Component 4: diabetes medication assessment

If the patient is on any glucose-lowering medication beyond the GLP-1 agent, the interaction needs explicit review. Sulphonylureas at doses appropriate before significant weight loss may now cause hypoglycaemia. Insulin doses may need reduction. Metformin typically continues unchanged but the full picture should be confirmed. [2] This component is frequently absent in private prescribing models where there is no connection to the patient's primary care record.

Component 5: body composition and lean mass assessment

Weight alone is an inadequate metric. A meaningful review includes waist circumference (the best proxy for visceral adipose tissue), current lean mass estimate where available, and a practical assessment of resistance training status. If lean mass has been significantly depleted during weight loss and resistance training is absent, the stopping risk profile is worse than the scale suggests. [3]

Component 6: the written 12-week plan

This is the component most consistently missing from informal stopping decisions. A written 12-week plan includes: monitoring frequency and method (daily weight trend, twice-weekly blood pressure if on antihypertensives); protein intake target; resistance training minimum; alcohol intake assessment; a specific weight threshold that triggers clinical review (e.g. 5% above exit weight); and a named date for a stopping review. Verbal reassurance is not a plan. A document that the patient can refer to when appetite returns at week four is.

What a GLP-1 Exit Strategy Review provides

A GLP-1 Exit Strategy Review with Dr Dan Reardon is a 60-minute clinical consultation covering all six components above. It produces a written plan. It reviews your medication list against your weight loss and blood pressure history. It identifies the specific monitoring priorities for your situation — not a generic leaflet. For patients stopping privately prescribed GLP-1 medication who have not had systematic clinical follow-up, it is the clinical step that should have been built into the prescription model from the start.